The 5-HT4 agonists cisapride, mosapride, and CJ-033466, a novel potent compound, exhibit different human Ether-a-go-go-Related Gene (hERG)-blocking activities

Journal of Pharmacological Sciences

Volumn 105, Issue 2, 2007, Pages 207-210

  Toga, Tetsuo ^a   Kohmura, Yumi ^a,b   Kawatsu, Ryoichi ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b WDB Co Ltd   (Japan)

Author keywords

5 HT4 agonist; Human ether a go go related gene (hERG); Patch clamp

Indexed keywords

CISAPRIDE; CJ 033466; MOSAPRIDE CITRATE; POTASSIUM CHANNEL HERG; SEROTONIN 4 AGONIST; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; EMBRYO; HUMAN; HUMAN CELL; PATCH CLAMP; WHOLE CELL;

EID: 36148991754     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.SC0070243     Document Type: Article

References (14)

1. FDA Talk Paper. Food and Drug Administration, U.S. Department of Health and Human Services. Janssen Pharmaceutica stops marketing cisapride in the US. T00-14, March 23, 2000. http:/ /www.fda.gov/bbs/topics/ANSWERS/ANS01007.html.
2. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
3. Kr potassium channel. Cell. 1995;81:299-307.
4. Pourrias B, Porsolt RD, Lacroix P. QT interval prolongation by noncardiovascular drugs: a proposed assessment strategy. Drug Development Res. 1999;47:55-62.
5. ICH S7B Guideline. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. May 12, 2005. http:/ /www.ich.org/LOB/media/MEDIA2192.pdf
6. + channel by the gastrointestinal prokinetics agent cisapride. Am J Physiol. 1997;273:H2534-H2538.
7. Rampe D, Roy M-L, Dennis A, Brown AM. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. 1997;417:28-32.
8. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, Qiu MR, et al. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol. 1999;128:444-450.
9. 4 receptor agonists on gastrointestinal motility in vivo. J Pharmacol Exp Ther. 1997;283:1000-1008.
10. Ruth M, Hamelin B, Röhss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1998;12:35-40.
11. 4-receptor agonists, cisapride, mosapride citrate, and zacopride, on cardiac action potentials in guinea pig isolated papillary muscles. J Cardiovasc Pharmacol. 1997;29:670-675.
12. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetics agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther. 1997;282:220-227.
13. + channel. J Pharmacol Exp Ther. 2001;299:1007-1012.
14. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophysical J. 1998;74:230-241.